Article List
List all articles in the database by earliest discovery_date
GET /articles/?page=2587
{ "count": 33445, "next": "http://api.gregory-ms.com/articles/?page=2588", "previous": "http://api.gregory-ms.com/articles/?page=2586", "results": [ { "article_id": 16084, "title": "Inter-joint coordination during gait in people with multiple sclerosis: A focus on the effect of disability", "summary": "Background\nWalking difficulties, which are widespread among people with MS (pwMS), represent one of the major factors contributing to physical disability and, as such, may greatly affect an individual's independence and quality of life. In this context, the study of lower limb kinematics may provide an important contribution to unveiling the underlying mechanisms of walking dysfunctions in MS. However, limited information about the inter-joint coordination during gait—the functional relationship between joint pairs during the whole gait cycle—is available.\nMethods\nWe retrospectively analyzed the gait patterns of 104 pwMS (56 women, 48 men, mean age 46.3, average Expanded Disability Status Scale score 3.5) and 84 unaffected individuals age-and-sex-matched, who underwent 3D computerized gait analysis carried out using an optical motion capture system. PwMS were also stratified into two groups according to their level of disability. Those with EDSS ≤ 3.5 (n = 62) formed the “low-mild disability” group, while those with EDSS > 3.5 (n = 42) were assigned to the “moderate-severe disability” group. The raw data were processed to calculate the main spatio-temporal parameters and the kinematics in the sagittal plane at the hip, knee, and ankle joints. At each point of the gait cycle, the angular values were employed to build angle-angle diagrams (cyclograms) for the hip-knee and the knee-ankle joint couples. Inter-joint coordination was quantified using geometric features of the cyclograms (i.e., area, perimeter, and dimensionless ratio) and compared between groups. For pwMS only, we also explored possible relationships between cyclograms parameters, disability level, and spatio-temporal parameters of gait.\nResults\nPwMS exhibit a well-known gait pattern characterized by reduced speed, stride length, increased step width, and double support phase duration. Their inter-joint coordination was found altered at both hip-knee and knee-ankle joint couples, as indicated by the significantly reduced cyclogram area and perimeter with respect to unaffected individuals. However, the detailed analysis of the angle-angle diagram trajectories showed some differences associated with the level of disability. In particular, pwMS with mild-low disability exhibit cyclograms partly superposed with those of unaffected individuals in the first half of the stance phase (hip-knee couple) and the second half of the swing phase (knee-ankle couple), while in those with a moderate-severe disability, the differences are substantially extended to the whole gait cycle. Significant moderate to large correlations were also observed between cyclogram area and perimeter, EDSS score, and spatio-temporal parameters of gait.\nConclusion\nThe study of inter-joint coordination during gait in pwMS represents a useful source of information about the way lower limb joints interact, thus potentially expanding the knowledge of the mechanisms underlying walking dysfunctions associated with the disease. From a clinical perspective, the availability of reference data for the co-variation of hip-knee and knee-ankle joint angles during gait can effectively support both the characterization of the progression of the disease and the assessment of the effectiveness of rehabilitative treatments.", "link": "https://www.msard-journal.com/article/S2211-0348(22)00256-5/fulltext", "published_date": "2022-03-12T00:00:00Z", "sources": [ "MS & Rel. Disorders" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 163687, "given_name": "Massimiliano", "family_name": "Pau", "ORCID": "http://orcid.org/0000-0001-9835-3629", "country": "IT" }, { "author_id": 259450, "given_name": "Bruno", "family_name": "Leban", "ORCID": null, "country": null }, { "author_id": 261826, "given_name": "Davide", "family_name": "Massa", "ORCID": null, "country": null }, { "author_id": 180387, "given_name": "Micaela", "family_name": "Porta", "ORCID": "http://orcid.org/0000-0003-3835-6507", "country": null }, { "author_id": 148572, "given_name": "Jessica", "family_name": "Frau", "ORCID": "http://orcid.org/0000-0001-9068-9144", "country": null }, { "author_id": 229606, "given_name": "Giancarlo", "family_name": "Coghe", "ORCID": "http://orcid.org/0000-0002-3796-3279", "country": null }, { "author_id": 148217, "given_name": "Eleonora", "family_name": "Cocco", "ORCID": "http://orcid.org/0000-0002-3878-8820", "country": null } ], "discovery_date": "2022-03-12T12:20:42.378184Z", "article_subject_relevances": [], "doi": "10.1016/j.msard.2022.103741", "access": "restricted", "takeaways": " The study of lower limb kinematics may provide an important contribution to unveiling the underlying mechanisms of walking dysfunctions in MS . We retrospectively analyzed the gait patterns of 104 pwMS (56 women, 48 men, mean age 46.3, average Expanded Disability Status Scale score 3.5)", "team_categories": [], "ml_predictions": [ { "gnb": null, "lr": null, "lsvc": null, "mnb": null, "created_date": "2024-05-25T01:54:24.264702Z", "subject": 1 } ] }, { "article_id": 16083, "title": "Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells", "summary": "Background\nIn the phase III, OPERA I and OPERA II, clinical trial lymphopenia was reported in 20.7% of relapsing–remitting multiple sclerosis (RRMS) patients taking Ocrelizumab (OCR).\nObjective\nThe objective of this study was to investigate the effect of OCR on lymphocyte subtypes in MS patients with and without lymphopenia.\nMethods\nRetrospective study comparing lymphocyte subtypes in OCR-treated MS patients with low (G1) and normal (G2) absolute lymphocyte count (ALC) at the six-month follow-up (cut-off: 1000 × 106/L). Mann Whitney U test was used to compare ALC, CD19, CD4 T, CD8 T and NK cell counts at baseline and at the six-month follow up between the two groups. A linear mixed model was applied to compare changes in ALC, and subset counts and proportions between patients with and without lymphopenia. We performed the same analyses in a subpopulation of naïve to treatment patients to exclude the possible influence of the previous disease modifying therapy (DMT) in the different kinetics observed between the two groups.\nResults\n: One hundred sixty-seven patients were included (G1, n = 34; G2, n = 133). At the six-month follow-up, compared with baseline, in the whole population we observed a significant reduction in ALC (p<0.0001), CD19 (p<0.0001) and CD8 T (p<0.0288) lymphocytes. We also found and increase in CD4/CD8 ratio after six months of treatment (p = 0.0098). G1 showed a lower ALC than G2 at baseline. At six months, mean ALC was 896.41 ± 156.25 × 106/L in G1 and 1909.9 ± 629.07 × 106/L in G2. CD4 and CD8 T cell mean counts were lower (p < 0.0001) in G1 than G2. At the linear mixed model analysis, we found a more pronounced increase in CD8 T percentage in G2 than G1 (p = 0.008). In the naïve to treatment group fifty patients were included. CD4 and CD8 T cell mean counts at six months were lower (p = 0.0074 and p = 0.0032, respectively) in G1 than G2. At the linear mixed model analysis, we found a more pronounced decrease of CD8 T cell count in G1 than G2 (p = 0.0103). Furthermore, we found an increase in CD8 T percentage in G2 whereas a profound decrease of CD8 T percentage was observed in G1 (p = 0.0052). After adjusting for confounders, significantly positive correlations were noted between ALC and both CD4 and CD8 T cell counts. Negative correlation was observed between ALC and CD4/CD8 ratio driven by low CD8 T cell counts.\nConclusion\nOCR decreases ALC. Among T cells, the treatment predominantly impacts CD8 cells. However, CD8 T cell decrease was more pronounced in patients with lymphopenia. Further studies are needed to establish the relationship between the effect of OCR on ALC and CD8 T cells and its potential implication in the early clinical response and risk for viral infections.", "link": "https://www.msard-journal.com/article/S2211-0348(22)00255-3/fulltext", "published_date": "2022-03-12T00:00:00Z", "sources": [ "MS & Rel. Disorders" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 177322, "given_name": "Gianmarco", "family_name": "Abbadessa", "ORCID": "http://orcid.org/0000-0001-8912-3055", "country": null }, { "author_id": 276617, "given_name": "Elisabetta", "family_name": "Maida", "ORCID": null, "country": null }, { "author_id": 152369, "given_name": "Giuseppina", "family_name": "Miele", "ORCID": "http://orcid.org/0000-0002-1910-5908", "country": null }, { "author_id": 152371, "given_name": "Luigi", "family_name": "Lavorgna", "ORCID": "http://orcid.org/0000-0003-4625-4236", "country": null }, { "author_id": 207541, "given_name": "Girolama Alessandra", "family_name": "Marfia", "ORCID": "http://orcid.org/0000-0001-5863-7758", "country": null }, { "author_id": 218934, "given_name": "Paola", "family_name": "Valentino", "ORCID": "http://orcid.org/0000-0001-7863-9195", "country": null }, { "author_id": 264758, "given_name": "Antonio", "family_name": "De Martino", "ORCID": null, "country": null }, { "author_id": 143661, "given_name": "Paola", "family_name": "Cavalla", "ORCID": "http://orcid.org/0000-0003-4589-4864", "country": null }, { "author_id": 148575, "given_name": "Simona", "family_name": "Bonavita", "ORCID": "http://orcid.org/0000-0002-8561-9720", "country": null } ], "discovery_date": "2022-03-12T12:20:42Z", "article_subject_relevances": [], "doi": "10.1016/j.msard.2022.103740", "access": "restricted", "takeaways": " In the phase III, OPERA I and OPERA II, clinical trial lymphopenia was reported in 20.7% of relapsing–remitting multiple sclerosis patients taking Ocrelizumab (OCR) The objective of this study was to investigate the effect of OCR on lymphocyte subtypes .", "team_categories": [ { "id": 6, "category_name": "Ocrelizumab", "category_description": "", "category_slug": "ocrelizumab", "category_terms": [ "ocrelizumab", "ocrevus" ] } ], "ml_predictions": [ { "gnb": null, "lr": null, "lsvc": null, "mnb": null, "created_date": "2024-05-25T01:54:42.503528Z", "subject": 1 } ] }, { "article_id": 15549, "title": "Magnetic resonance imaging criteria at onset to differentiate pediatric multiple sclerosis from acute disseminated encephalomyelitis: A nationwide cohort study", "summary": "Background\nBrain MRI is the critical in distinguishing pediatric MS from acute disseminated encephalomyelitis (ADEM). Our aim was to propose MRI criteria to distinguish MS from monophasic ADEM based on the first brain MRI and to validate previously proposed MRI criteria.\nMethods\nA neuroradiologist undertook retrospective evaluation of the MRI at the first demyelinating event in children (<18 years) with medical record-validated MS and ADEM in Denmark during 2008–15. We used forward stepwise logistic regression to identify MRI categories that differed significantly between MS and ADEM. We estimated accuracy statistics for all MRI criteria to distinguish MS from ADEM.\nResults\nThe monophasic ADEM cohort (n=46) was nationwide and population-based during 2008–15; the median age at onset of 5.3 years (range 0.8‒17.2) and children had at least five years of follow-up to ensure a monophasic disease course. Children with MS (n=67) had a median age at onset of 16.3 years (range 3.3‒17.9). Having at least two categories best distinguished MS from monophasic ADEM by an area under the curve of 83% to 89%: (a) corpus callosum long axis perpendicular lesion; (b) only well-defined lesions; (c) absence of basal ganglia or thalamus lesion OR, (a) corpus callosum long axis perpendicular lesion; (b) only well-defined lesions; (c) absence of diffuse large lesions; (d) black holes. The Callen, KIDMUS, and IPMSSG criteria performed well. The McDonald 2017, Barkhof, MAGNIMS, and Verhey criteria had poorer performance.\nConclusion\nThis study provides Class II evidence that brain MRI has good performance in differentiating MS from monophasic ADEM at onset.", "link": "https://www.msard-journal.com/article/S2211-0348(22)00253-X/fulltext", "published_date": "2022-03-11T00:00:00Z", "sources": [ "MS & Rel. Disorders" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 174442, "given_name": "Magnus Spangsberg", "family_name": "Boesen", "ORCID": "http://orcid.org/0000-0002-2788-1974", "country": null }, { "author_id": 255149, "given_name": "Morten", "family_name": "Blinkenberg", "ORCID": null, "country": null }, { "author_id": 247051, "given_name": "Lau Caspar", "family_name": "Thygesen", "ORCID": null, "country": null }, { "author_id": 256178, "given_name": "Jurgita", "family_name": "Ilginiene", "ORCID": null, "country": null }, { "author_id": 213849, "given_name": "Annika Reynberg", "family_name": "Langkilde", "ORCID": "http://orcid.org/0000-0003-0848-5834", "country": null } ], "discovery_date": "2022-03-12T04:40:42Z", "article_subject_relevances": [], "doi": "10.1016/j.msard.2022.103738", "access": "restricted", "takeaways": " Brain MRI is critical in distinguishing pediatric MS from acute disseminated encephalomyelitis (ADEM) Our aim was to propose MRI criteria to distinguish MS from ADEM based on the first brain MRI . We used forward stepwise logistic regression to identify MRI categories that differed significantly between MS and ADEM . Having at least two categories best distinguished MS from monophasic ADEM by an area under the curve of 83% to 89%.", "team_categories": [], "ml_predictions": [ { "gnb": null, "lr": null, "lsvc": null, "mnb": null, "created_date": "2024-05-25T01:54:43.471824Z", "subject": 1 } ] }, { "article_id": 15043, "title": "Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis", "summary": "Background\n: Prior studies suggest reduced humoral response to COVID-19 vaccination in immunosuppressed populations. Disease modifying therapies (DMTs) for multiple sclerosis (MS) have variable immunomodulatory effects, and limited data are available for all DMTs. We aimed to determine the impact of DMTs on antibody response to COVID-19 vaccination among MS patients.\nMethods\n: Patients with documented COVID-19 vaccination dates and anti-spike antibody results post-vaccination were identified between March-August 2021. Clinical data were retrospectively abstracted from chart review. Deidentified data were analyzed to evaluate antibody response, and multivariable logistic regression analyses were used to identify clinical and demographic predictors of antibody response. Data analysis was completed with SAS Studio, v3.8.\nResults\n: A total of 353 individuals had documented COVID-19 vaccine and antibody test dates (58% Pfizer, 38% Moderna, and 4% Johnson & Johnson). Of these 353 patients, 72% developed antibodies, with a mean antibody test interval of 53 days (median 46) post final vaccine dose. 100% of those on no DMT (n=34), injectables (n=20), teriflunomide (n=10), natalizumab (n=71), and 97.8% of those on fumarates (n=46/47) had a positive antibody result. One patient on cladribine (n=1) had a negative antibody result. Of those on sphingosine-1 phosphate (S1P) modulators, 72.4% (n=21/29) had a positive antibody result. Of those on anti-CD20 therapies, 37.6% (n=53/141) had a positive antibody result. Multivariate modeling of the total cohort showed anti-CD20 therapy was significantly associated with lower odds of positive antibody response (OR=0.024, 95% CI 0.01;0.05, p<0.0001). Among S1P modulators, increased duration of therapy, and not lymphopenia, may be associated with lower odds of positive antibody response. Multivariate modeling of anti-CD20 therapies showed therapy duration <1 year (OR 8.14, 95% CI 2.896;22.898 p<.0001) and prior COVID-19 infection (OR=3.95, 95% CI 1.137;13.726, p=.03) were significantly associated with higher odds of a positive antibody response. In patients with recent B-cell data, mean B-cell count was higher in antibody-positive individuals compared to antibody-negative (32.9 vs. 3.9 cells, p=.0056).\nConclusion\n: MS DMTs had variable impact on antibody response with mRNA and viral vector COVID-19 vaccines. All patients on no DMT, interferons, glatiramer acetate, teriflunomide, natalizumab, and nearly all on fumarates had positive antibody responses post-vaccine. S1P modulators and anti-CD20 therapies attenuated antibody response post-vaccine. For patients on anti-CD20 therapies, shorter duration of therapy and prior COVID-19 infection predicted positive antibody response. Further studies are needed to determine clinical significance of antibody testing, development of cellular mediated immunity, and benefits of booster vaccinations.", "link": "https://www.msard-journal.com/article/S2211-0348(22)00252-8/fulltext", "published_date": "2022-03-11T00:00:00Z", "sources": [ "MS & Rel. Disorders" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 333507, "given_name": "Sammita", "family_name": "Satyanarayan", "ORCID": "http://orcid.org/0000-0002-0300-4969", "country": null }, { "author_id": 261807, "given_name": "Neha", "family_name": "Safi", "ORCID": null, "country": null }, { "author_id": 285764, "given_name": "Tali", "family_name": "Sorets", "ORCID": null, "country": null }, { "author_id": 289945, "given_name": "Susan", "family_name": "Filomena", "ORCID": null, "country": null }, { "author_id": 324219, "given_name": "Yinan", "family_name": "Zhang", "ORCID": "http://orcid.org/0000-0001-9934-4564", "country": null }, { "author_id": 165746, "given_name": "Sylvia", "family_name": "Klineova", "ORCID": "http://orcid.org/0000-0002-0406-0460", "country": null }, { "author_id": 253789, "given_name": "Michelle", "family_name": "Fabian", "ORCID": null, "country": null }, { "author_id": 253788, "given_name": "Sam", "family_name": "Horng", "ORCID": null, "country": null }, { "author_id": 289948, "given_name": "Stephanie", "family_name": "Tankou", "ORCID": null, "country": null }, { "author_id": 241112, "given_name": "Aaron", "family_name": "Miller", "ORCID": null, "country": null }, { "author_id": 240958, "given_name": "Stephen", "family_name": "Krieger", "ORCID": null, "country": null }, { "author_id": 246974, "given_name": "Fred", "family_name": "Lublin", "ORCID": null, "country": null }, { "author_id": 289951, "given_name": "James", "family_name": "Sumowski", "ORCID": null, "country": null }, { "author_id": 174425, "given_name": "Ilana", "family_name": "Katz Sand", "ORCID": "http://orcid.org/0000-0001-5107-4761", "country": null } ], "discovery_date": "2022-03-11T21:00:42Z", "article_subject_relevances": [], "doi": "10.1016/j.msard.2022.103737", "access": "open", "takeaways": " Prior studies suggest reduced humoral response to COVID-19 vaccination in immunosuppressed populations . Disease modifying therapies (DMTs) for multiple sclerosis have variable immunomodulatory effects . We aimed to determine the impact of DMTs on antibody response to vaccination among MS patients . Of those on anti-CD20 therapies, 37.6% (n=53/141) had a positive antibody result .", "team_categories": [ { "id": 5, "category_name": "Natalizumab", "category_description": "", "category_slug": "natalizumab", "category_terms": [ "natalizumab", "tysabri" ] }, { "id": 37, "category_name": "Aubagio", "category_description": "Aubagio is a medicine that contains the active substance teriflunomide. It is used to treat patients from the age of 10 years with multiple sclerosis (MS), a disease in which inflammation destroys the protective sheath around the nerves. \r\n\r\nAubagio is used in the type of MS known as relapsing-remitting MS, when the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).", "category_slug": "aubagio", "category_terms": [ "teriflunomide", "aubagio" ] } ], "ml_predictions": [ { "gnb": null, "lr": null, "lsvc": null, "mnb": null, "created_date": "2024-05-25T01:52:53.753506Z", "subject": 1 } ] }, { "article_id": 14808, "title": "Transcriptomic characterization of tissues from patients and subsequent pathway analyses reveal biological pathways that are implicated in spastic ataxia", "summary": "Background: Spastic ataxias (SAs) encompass a group of rare and severe neurodegenerative diseases, characterized by an overlap between ataxia and spastic paraplegia clinical features. They have been associated with pathogenic variants in a number of genes, including GBA2. This gene codes for the non-lysososomal β-glucosylceramidase, which is involved in sphingolipid metabolism through its catalytic role in the degradation of glucosylceramide. However, the mechanism by which GBA2 variants lead to the development of SA is still unclear.MethodsIn this work, we perform next-generation RNA-sequencing (RNA-seq), in an attempt to discover differentially expressed genes (DEGs) in lymphoblastoid, fibroblast cell lines and induced pluripotent stem cell-derived neurons derived from patients with SA, homozygous for the GBA2 c.1780G > C missense variant. We further exploit DEGs in pathway analyses in order to elucidate candidate molecular mechanisms that are implicated in the development of the GBA2 gene-associated SA.ResultsOur data reveal a total of 5217 genes with significantly altered expression between patient and control tested tissues. Furthermore, the most significant extracted pathways are presented and discussed for their possible role in the pathogenesis of the disease. Among them are the oxidative stress, neuroinflammation, sphingolipid signaling and metabolism, PI3K-Akt and MAPK signaling pathways.ConclusionsOverall, our work examines for the first time the transcriptome profiles of GBA2-associated SA patients and suggests pathways and pathway synergies that could possibly have a role in SA pathogenesis. Lastly, it provides a list of DEGs and pathways that could be further validated towards the discovery of disease biomarkers.", "link": "https://cellandbioscience.biomedcentral.com/articles/10.1186/s13578-022-00754-1", "published_date": "2022-03-11T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Cell & Bioscience", "authors": [ { "author_id": 289900, "given_name": "Andrea C.", "family_name": "Kakouri", "ORCID": null, "country": null }, { "author_id": 289902, "given_name": "Christina", "family_name": "Votsi", "ORCID": null, "country": null }, { "author_id": 289904, "given_name": "Anastasis", "family_name": "Oulas", "ORCID": null, "country": null }, { "author_id": 289905, "given_name": "Paschalis", "family_name": "Nicolaou", "ORCID": null, "country": null }, { "author_id": 289906, "given_name": "Massimo", "family_name": "Aureli", "ORCID": null, "country": null }, { "author_id": 289907, "given_name": "Giulia", "family_name": "Lunghi", "ORCID": null, "country": null }, { "author_id": 289908, "given_name": "Maura", "family_name": "Samarani", "ORCID": null, "country": null }, { "author_id": 289909, "given_name": "Giacomo M.", "family_name": "Compagnoni", "ORCID": null, "country": null }, { "author_id": 289910, "given_name": "Sabrina", "family_name": "Salani", "ORCID": null, "country": null }, { "author_id": 238082, "given_name": "Alessio", "family_name": "Di Fonzo", "ORCID": null, "country": null }, { "author_id": 289911, "given_name": "Thalis", "family_name": "Christophides", "ORCID": null, "country": null }, { "author_id": 289912, "given_name": "George A.", "family_name": "Tanteles", "ORCID": null, "country": null }, { "author_id": 289913, "given_name": "Eleni", "family_name": "Zamba-Papanicolaou", "ORCID": null, "country": null }, { "author_id": 167873, "given_name": "Marios", "family_name": "Pantzaris", "ORCID": "http://orcid.org/0000-0003-2937-384X", "country": null }, { "author_id": 155423, "given_name": "George M.", "family_name": "Spyrou", "ORCID": "http://orcid.org/0000-0002-2470-3363", "country": null }, { "author_id": 204528, "given_name": "Christodoulou", "family_name": "Kyproula", "ORCID": "http://orcid.org/0000-0002-0622-7594", "country": null } ], "discovery_date": "2022-03-11T18:17:48.566782Z", "article_subject_relevances": [], "doi": "10.1186/s13578-022-00754-1", "access": "open", "takeaways": " Spastic ataxias encompass a group of rare and severe neurodegenerative diseases, characterized by an overlap between ataxia and spastic paraplegia clinical features . The mechanism by which GBA2 variants lead to the development of SA is still unclear .", "team_categories": [], "ml_predictions": [ { "gnb": null, "lr": null, "lsvc": null, "mnb": null, "created_date": "2024-05-25T01:57:50.243801Z", "subject": 1 } ] }, { "article_id": 14805, "title": "Elevated serum extracellular vesicle arginase 1 in type 2 diabetes mellitus: a cross-sectional study in middle-aged and elderly population", "summary": "Background: Serum extracellular vesicle (EV)-derived arginase 1 (ARG 1) plays a critical role in diabetes-associated endothelial dysfunction. This study was performed to determine the levels of serum EV-derived ARG 1 in T2DM and non-T2DM participants and to examine the association of serum EV-derived ARG 1 with T2DM incidence.MethodsWe performed a cross-sectional study in 103 Chinese, including 73 T2DM patients and 30 non-T2DM. Serum EVs were prepared via ultracentrifugation. Serum EV-derived ARG 1 levels were measured by enzyme-linked immunosorbent assay. The correlations between serum EV-derived ARG 1 and clinical variables were analyzed. The association of serum EV-derived ARG 1 levels with T2DM was determined by multivariate logistic regression analysis. Interaction subgroup analysis was used to evaluate the interaction of the relevant baselines on the association between serum EV-derived ARG 1 levels and T2DM.ResultsSerum EV-derived ARG 1 levels were significantly higher in T2DM patients compared with non-T2DM patients (p < 0.001). Correlation analysis revealed that serum EV-derived ARG 1 levels were positively associated with fasting plasma glucose (FPG) (r = 0.316, p = 0.001) and glycated hemoglobin (HbA1c) (r = 0.322, p = 0.001). Serum EV-derived ARG 1 levels were significantly associated with T2DM, especially in the subgroup of T2DM for more than 10 years (OR 1.651, 95% CI = 1.066–2.557; P value, 0.025), after adjusting for confounding factors.ConclusionsElevated concentration of serum EV-derived ARG 1 is closely associated with T2DM.", "link": "https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00982-z", "published_date": "2022-03-11T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Endocrine Disorders", "authors": [ { "author_id": 309054, "given_name": "Xinwei", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 309055, "given_name": "Wen", "family_name": "Zhao", "ORCID": null, "country": null }, { "author_id": 309056, "given_name": "Lu", "family_name": "Peng", "ORCID": null, "country": null }, { "author_id": 245698, "given_name": "Yu", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 309057, "given_name": "Shaoping", "family_name": "Nie", "ORCID": null, "country": null }, { "author_id": 309058, "given_name": "Huahui", "family_name": "Yu", "ORCID": null, "country": null }, { "author_id": 309059, "given_name": "Yanwen", "family_name": "Qin", "ORCID": null, "country": null }, { "author_id": 309060, "given_name": "Huina", "family_name": "Zhang", "ORCID": null, "country": null } ], "discovery_date": "2022-03-11T18:17:48.563953Z", "article_subject_relevances": [], "doi": "10.1186/s12902-022-00982-z", "access": "open", "takeaways": " Serum extracellular vesicle (EV)-derived arginase 1 (ARG 1) plays a critical role in diabetes-associated endothelial dysfunction . This study was performed to determine the levels of serum EV-derived ARG 1 in T2DM and non-T2DM participants .", "team_categories": [], "ml_predictions": [ { "gnb": null, "lr": null, "lsvc": null, "mnb": null, "created_date": "2024-05-25T01:53:17.392975Z", "subject": 1 } ] }, { "article_id": 14804, "title": "Chromatin accessibility and transcriptome integrative analysis revealed AP-1-mediated genes potentially modulate histopathology features in psoriasis", "summary": "Background: Psoriasis is a chronic and hyperproliferative skin disease featured by hyperkeratosis with parakeratosis, Munro micro-abscess, elongation of rete pegs, granulosa thinning, and lymphocyte infiltration. We previously profiled gene expression and chromatin accessibility of psoriatic skins by transcriptome sequencing and ATAC-seq. However, integrating both of these datasets to unravel gene expression regulation is lacking. Here, we integrated transcriptome and ATAC-seq of the same psoriatic and normal skin tissues, trying to leverage the potential role of chromatin accessibility and their function in histopathology features. ResultsBy inducing binding and expression target analysis (BETA) algorithms, we explored the target prediction of transcription factors binding in 15 psoriatic and 19 control skins. BETA identified 408 upregulated genes (rank product < 0.01) and 133 downregulated genes linked with chromatin accessibility. We noticed that cumulative fraction of genes in upregulation group was statistically higher than background, while that of genes in downregulation group was not significant. KEGG pathway analysis showed that the upregulated 408 genes were enriched in TNF, NOD, and IL-17 signaling pathways. In addition, the motif module in BETA suggested the 57 upregulated genes are targeted by transcription factor AP-1, indicating that increased chromatin accessibility facilitated the binding of AP-1 to the target regions and further induced expression of relevant genes. Among these genes, SQLE, STRN, EIF4, and MYO1B expression was increased in patients with hyperkeratosis, parakeratosis, and acanthosis thickening.ConclusionsIn summary, with the advantage of BETA, we identified a series of genes that contribute to the disease pathogenesis, especially in modulating histopathology features, providing us with new clues in treating psoriasis.", "link": "https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-022-01250-6", "published_date": "2022-03-11T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Clinical Epigenetics", "authors": [ { "author_id": 289919, "given_name": "Xiaoqing", "family_name": "Xu", "ORCID": null, "country": null }, { "author_id": 289920, "given_name": "Xianfa", "family_name": "Tang", "ORCID": null, "country": null }, { "author_id": 289921, "given_name": "Yuxi", "family_name": "Zhang", "ORCID": null, "country": null }, { "author_id": 289922, "given_name": "Zhaobing", "family_name": "Pan", "ORCID": null, "country": null }, { "author_id": 289923, "given_name": "Qingping", "family_name": "Wang", "ORCID": null, "country": null }, { "author_id": 250430, "given_name": "Lili", "family_name": "Tang", "ORCID": null, "country": null }, { "author_id": 289924, "given_name": "Caihong", "family_name": "Zhu", "ORCID": null, "country": null }, { "author_id": 289925, "given_name": "Hui", "family_name": "Cheng", "ORCID": null, "country": null }, { "author_id": 224701, "given_name": "Fusheng", "family_name": "Zhou", "ORCID": "http://orcid.org/0000-0003-4195-2801", "country": null } ], "discovery_date": "2022-03-11T18:17:48.562635Z", "article_subject_relevances": [], "doi": "10.1186/s13148-022-01250-6", "access": "open", "takeaways": " Psoriasis is a chronic and hyperproliferative skin disease featured by hyperkeratosis with parakeratosis, Munro micro-abscess, elongation of rete pegs, granulosa thinning, and lymphocyte infiltration . We previously profiled gene expression and chromatin accessibility of psoriatic skins by transcriptome sequencing and ATAC-seq .", "team_categories": [], "ml_predictions": [ { "gnb": null, "lr": null, "lsvc": null, "mnb": null, "created_date": "2024-05-25T01:52:10.779624Z", "subject": 1 } ] }, { "article_id": 14746, "title": "Association of Socioeconomic Disadvantage and Neighborhood Disparities with Clinical Outcomes in Multiple Sclerosis Patients", "summary": "Background: Socioeconomic disadvantage may be an important contributor to clinical outcomes in MS but is not well understood. Our objective was to examine the associations between Area Deprivation Index (ADI), a validated measure of neighborhood-level disadvantage, with clinical outcomes.\nMethods: We assessed the longitudinal association between MS Performance Test (MSPT) and quality of life in Neurological Disorders (Neuro-QoL) measures with ADI quartiles (Q1: lowest deprivation – Q4 highest deprivation) in relapsing remitting MS (RRMS) and progressive MS cohorts.\nResults: Our study included 2,921 patients (65.8% RRMS and 34.1% progressive MS) with 13,715 visits. Patients living in the most disadvantaged areas had almost universal worsening on baseline MSPT and Neuro-QoL scores (p < 0.05) when compared to patients living in areas of lowest deprivation. Manual Dexterity Test (MDT) illustrated particular disparity as RRMS patients living in the greatest area of deprivation had MDT score which averaged 2.9 seconds longer than someone living in areas of least deprivation. Longitudinal analysis illustrated less favorable MSPT and Neuro-QoL outcomes across visits between Q1 versus Q4 ADI quartiles within in the RRMS cohort but not within the progressive MS cohort. After adjustment, linearly increasing area deprivation scores reflected less favorable Processing Speed Test (PST) and six Neuro-QoL outcomes among the RRMS cohort. Within the progressive cohort, higher deprivation was associated less favorable MDT, PST and 11 of 12 Neuro-QoL outcome measures.\nConclusions: This study provides evidence for socioeconomic disadvantage as a risk factor for disability accrual in MS and may be targeted to improve care while informing resource allocation.", "link": "https://www.msard-journal.com/article/S2211-0348(22)00249-8/fulltext", "published_date": "2022-03-11T00:00:00Z", "sources": [ "MS & Rel. Disorders" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 155596, "given_name": "Justin R.", "family_name": "Abbatemarco", "ORCID": "http://orcid.org/0000-0003-1668-4753", "country": null }, { "author_id": 295594, "given_name": "Alise", "family_name": "Carlson", "ORCID": null, "country": null }, { "author_id": 157754, "given_name": "Daniel", "family_name": "Ontaneda", "ORCID": "http://orcid.org/0000-0002-2838-9148", "country": null }, { "author_id": 261137, "given_name": "Marisa", "family_name": "McGinley", "ORCID": null, "country": null }, { "author_id": 150024, "given_name": "Robert A.", "family_name": "Bermel", "ORCID": "http://orcid.org/0000-0003-2334-6883", "country": null }, { "author_id": 259847, "given_name": "Scott", "family_name": "Husak", "ORCID": null, "country": null }, { "author_id": 295595, "given_name": "David", "family_name": "Bruckman", "ORCID": null, "country": null }, { "author_id": 295596, "given_name": "Jesse D.", "family_name": "Schold", "ORCID": null, "country": null }, { "author_id": 283109, "given_name": "Deborah M.", "family_name": "Miller", "ORCID": null, "country": null } ], "discovery_date": "2022-03-11T17:10:44Z", "article_subject_relevances": [], "doi": "10.1016/j.msard.2022.103734", "access": "restricted", "takeaways": " Socioeconomic disadvantage may be an important contributor to clinical outcomes in MS but is not well understood . Study included 2,921 patients (65.8% RRMS and 34.1% progressive MS) with 13,715 visits . Patients living in the most disadvantaged areas had almost universal worsening on baseline MSPT and Neuro-QoL scores .", "team_categories": [], "ml_predictions": [ { "gnb": null, "lr": null, "lsvc": null, "mnb": null, "created_date": "2024-05-25T01:51:42.209909Z", "subject": 1 } ] }, { "article_id": 14538, "title": "Timed Up & Go (TUG) With Cognitive and Manual Tasks: Multiple Sclerosis", "summary": "Timed Up & Go (TUG) With Cognitive and Manual Tasks – Multiple Sclerosis", "link": "https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/timed-up--go-tug-with-cognitive-and-manual-tasks-multiple-sclerosis", "published_date": "2022-03-11T14:20:18.802000Z", "sources": [ "APTA" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": null, "container_title": null, "authors": [], "discovery_date": "2022-03-11T14:17:49.099306Z", "article_subject_relevances": [], "doi": null, "access": "unknown", "takeaways": null, "team_categories": [], "ml_predictions": [ { "gnb": null, "lr": null, "lsvc": null, "mnb": null, "created_date": "2024-05-25T01:57:46.139304Z", "subject": 1 } ] }, { "article_id": 14512, "title": "Computational pathology for musculoskeletal conditions using machine learning: advances, trends, and challenges", "summary": "AbstractHistopathology is widely used to analyze clinical biopsy specimens and tissues from pre-clinical models of a variety of musculoskeletal conditions. Histological assessment relies on scoring systems that require expertise, time, and resources, which can lead to an analysis bottleneck. Recent advancements in digital imaging and image processing provide an opportunity to automate histological analyses by implementing advanced statistical models such as machine learning and deep learning, which would greatly benefit the musculoskeletal field. This review provides a high-level overview of machine learning applications, a general pipeline of tissue collection to model selection, and highlights the development of image analysis methods, including some machine learning applications, to solve musculoskeletal problems. We discuss the optimization steps for tissue processing, sectioning, staining, and imaging that are critical for the successful generalizability of an automated image analysis model. We also commenting on the considerations that should be taken into account during model selection and the considerable advances in the field of computer vision outside of histopathology, which can be leveraged for image analysis. Finally, we provide a historic perspective of the previously used histopathological image analysis applications for musculoskeletal diseases, and we contrast it with the advantages of implementing state-of-the-art computational pathology approaches. While some deep learning approaches have been used, there is a significant opportunity to expand the use of such approaches to solve musculoskeletal problems.", "link": "https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-021-02716-3", "published_date": "2022-03-11T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory", "is_active": true, "created": "2024-05-04T18:35:11.961532Z", "modified": "2024-07-04T10:58:33.274216Z", "slug": "team-gregory", "users": [ 3, 1 ] } ], "subjects": [ { "id": 1, "subject_name": "Multiple Sclerosis", "description": null, "team_id": 1 } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Arthritis Research & Therapy", "authors": [ { "author_id": 215423, "given_name": "Maxwell A.", "family_name": "Konnaris", "ORCID": "http://orcid.org/0000-0003-4893-1413", "country": null }, { "author_id": 262134, "given_name": "Matthew", "family_name": "Brendel", "ORCID": null, "country": null }, { "author_id": 262135, "given_name": "Mark Alan", "family_name": "Fontana", "ORCID": null, "country": null }, { "author_id": 262136, "given_name": "Miguel", "family_name": "Otero", "ORCID": null, "country": null }, { "author_id": 262138, "given_name": "Lionel B.", "family_name": "Ivashkiv", "ORCID": null, "country": null }, { "author_id": 240342, "given_name": "Fei", "family_name": "Wang", "ORCID": null, "country": null }, { "author_id": 215428, "given_name": "Richard D.", "family_name": "Bell", "ORCID": "http://orcid.org/0000-0003-1562-3879", "country": null } ], "discovery_date": "2022-03-11T14:17:48.400238Z", "article_subject_relevances": [], "doi": "10.1186/s13075-021-02716-3", "access": "open", "takeaways": " Histopathology is widely used to analyze clinical biopsy specimens and tissues from pre-clinical models of a variety of musculoskeletal conditions . Recent advancements in digital imaging and image processing provide an opportunity to automate histological analyses by implementing advanced statistical models such as machine learning and deep learning .", "team_categories": [], "ml_predictions": [ { "gnb": null, "lr": null, "lsvc": null, "mnb": null, "created_date": "2024-05-25T01:52:28.405708Z", "subject": 1 } ] } ] }